Cutaneous Cryoglobulinemic Vasculitis

  • Konstantinos Linos
  • Bernard Cribier
  • J. Andrew Carlson


The Chapel Hill Consensus Conference criteria define cryoglobulinemic vasculitis (CV) as “vasculitis, with cryoglobulin immune deposits, affecting small vessels (i.e. capillaries, venules, or arterioles), and associated with cryoglobulins in the serum.” Hepatitis C virus (HCV) infection is the underlying etiologic factor in the majority of cases of CV, but it also occurs secondary to other infections (e.g., hepatitis B), connective tissue diseases (e.g., Sjögren’s syndrome), and hematolymphoid proliferations (e.g., Waldenström’s macroglobulinemia). Purpura, arthralgia, and weakness are the most common presenting signs and symptoms but any organ can be affected (skin, kidney, and nerves most frequently). The extent of involvement and disease severity progress with time in the absence of treatment. Recurrent palpable purpura associated with post-inflammatory hyperpigmenation is the most frequent cutaneous manifestation of CV but others include nodules, leg ulcers, livedo racemosa, and digital gangrene, i.e., signs of muscular-vessel vasculitis. Skin biopsy shows a small-vessel neutrophilic vasculitis equally affecting superficial and deep dermal and subcutis vessels, with neutrophilic muscular-vessel vasculitis in a minority of cases. Thrombosis, in some instances by hyaline/ type I cryoglobulin thrombi, contributes to the ischemic damage. By direct immunofluorescence, abundant IgM, and complement deposits are found in the affected vessels, highlighting the immune-complex mediated pathogenesis. Adverse prognostic factors for HCV-related CV include the presence of ulcers and renal insufficiency. Anti-HCV therapy (interferon-α and ribavirin) with or without rituximab is associated with a favorable clinical response, but relapse is common. In some patients, the persistent CV necessitates the administration of immunosuppressive agents.


Mixed Cryoglobulinemia Cutaneous Vasculitis Urticarial Vasculitis Palpable Purpura Cryoglobulinemic Vasculitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Meltzer M, Franklin EC, Elias K et al (1966) Cryoglo­bulinemia – a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 40(6):837–856PubMedCrossRefGoogle Scholar
  2. 2.
    Cacoub P, Costedoat-Chalumeau N, Lidove O, Alric L (2002) Cryoglobulinemia vasculitis. Curr Opin Rheumatol 14(1):29–35PubMedCrossRefGoogle Scholar
  3. 3.
    Ferri C, Zignego AL, Giuggioli D et al (2002) HCV and cryoglobulinemic vasculitis. Cleve Clin J Med 69(Suppl 2):SII20–SII23PubMedCrossRefGoogle Scholar
  4. 4.
    Gorevic PD, Kassab HJ, Levo Y et al (1980) Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 69(2):287–308PubMedCrossRefGoogle Scholar
  5. 5.
    Sansonno D, Dammacco F (2005) Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 5(4):227–236PubMedCrossRefGoogle Scholar
  6. 6.
    Brouet JC, Clauvel JP, Danon F et al (1974) Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57(5):775–788PubMedCrossRefGoogle Scholar
  7. 7.
    Tedeschi A, Barate C, Minola E, Morra E (2007) Cryoglobulinemia. Blood Rev 21(4):183–200PubMedCrossRefGoogle Scholar
  8. 8.
    Cacoub P, Saadoun D (2008) Hepatitis C virus infection induced vasculitis. Clin Rev Allergy Immunol 35(1–2):30–39PubMedCrossRefGoogle Scholar
  9. 9.
    Carlson JA, Ng BT, Chen KR (2005) Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol 27(6):504–528PubMedCrossRefGoogle Scholar
  10. 10.
    Jennette JC, Falk RJ (2000) Overview of the nomenclature and diagnostic categorization of vasculitis. Wien Klin Wochenschr 112(15–16):650–655PubMedGoogle Scholar
  11. 11.
    Gungor E, Cirit A, Alli N et al (1999) Prevalence of hepatitis C virus antibodies and cryoglobulinemia in patients with leukocytoclastic vasculitis. Dermatology 198(1):26–28PubMedCrossRefGoogle Scholar
  12. 12.
    Sais G, Vidaller A, Jucgla A et al (1998) Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol 134(3):309–315PubMedCrossRefGoogle Scholar
  13. 13.
    Gonzalez-Gay MA, Garcia-Porrua C (1999) Systemic vasculitis in adults in northwestern Spain, 1988–1997. Clinical and epidemiologic aspects. Medicine (Baltimore) 78(5):292–308CrossRefGoogle Scholar
  14. 14.
    Ferri C (2008) Mixed cryoglobulinemia. Orphanet J Rare Dis 3:25PubMedCrossRefGoogle Scholar
  15. 15.
    Herrine SK (2002) Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 136(10):747–757PubMedCrossRefGoogle Scholar
  16. 16.
    Dispenzieri A, Gorevic PD (1999) Cryoglobulinemia. Hematol Oncol Clin North Am 13(6):1315–1349PubMedCrossRefGoogle Scholar
  17. 17.
    Lamprecht P, Gause A, Gross WL (1999) Cryoglobulinemic vasculitis. Arthritis Rheum 42(12):2507–2516PubMedCrossRefGoogle Scholar
  18. 18.
    Braun GS, Horster S, Wagner K et al (2007) Cryoglo­bulinaemic vasculitis: classification and clinical and therapeutic aspects. Postgrad Med J 83(976):87–94PubMedCrossRefGoogle Scholar
  19. 19.
    Gumber SC, Chopra S (1995) Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 123(8):615–620PubMedCrossRefGoogle Scholar
  20. 20.
    Bombardieri S, Ferri C, Migliorini P et al (1986) Cryoglobulins and immune complexes in essential mixed cryoglobulinemia. Ric Clin Lab 16(2):281–288PubMedGoogle Scholar
  21. 21.
    Levo Y, Gorevic PD, Kassab HJ et al (1977) Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med 296(26):1501–1504PubMedCrossRefGoogle Scholar
  22. 22.
    Pascual M, Perrin L, Giostra E, Schifferli JA (1990) Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 162(2):569–570PubMedCrossRefGoogle Scholar
  23. 23.
    Abel G, Zhang QX, Agnello V (1993) Hepatitis C virus infection in type II mixed cryoglobulinemia. Arthritis Rheum 36(10):1341–1349PubMedCrossRefGoogle Scholar
  24. 24.
    Monti G, Galli M, Invernizzi F et al (1995) Cryoglo­bulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian group for the study of cryoglobulinaemias. QJM 88(2):115–126PubMedGoogle Scholar
  25. 25.
    Ferri C, Sebastiani M, Giuggioli D et al (2004) Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 33(6):355–374PubMedCrossRefGoogle Scholar
  26. 26.
    Ferri C, La Civita L, Longombardo G et al (1993) Hepatitis C virus and mixed cryoglobulinaemia. Eur J Clin Invest 23(7):399–405PubMedCrossRefGoogle Scholar
  27. 27.
    Monti G, Pioltelli P, Saccardo F et al (2005) Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 165(1):101–105PubMedCrossRefGoogle Scholar
  28. 28.
    Ramos-Casals M, Munoz S, Medina F et al (2009) Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (the HISPAMEC registry). J Rheumatol 36(7):1442–1448PubMedCrossRefGoogle Scholar
  29. 29.
    Santagostino E, Colombo M, Cultraro D et al (1998) High prevalence of serum cryoglobulins in multitransfused hemophilic patients with chronic hepatitis C. Blood 92(2):516–519PubMedGoogle Scholar
  30. 30.
    Lunel F, Musset L, Cacoub P et al (1994) Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 106(5):1291–1300PubMedGoogle Scholar
  31. 31.
    Pawlotsky JM, Ben Yahia M, Andre C et al (1994) Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 19(4):841–848PubMedCrossRefGoogle Scholar
  32. 32.
    Ramos-Casals M, Font J (2005) Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol 17(4):447–455PubMedGoogle Scholar
  33. 33.
    Agnello V (1998) Mixed cryoglobulinaemia after hepatitis C virus: more and less ambiguity. Ann Rheum Dis 57(12):701–702PubMedCrossRefGoogle Scholar
  34. 34.
    Ferri C, Mascia MT (2006) Cryoglobulinemic vasculitis. Curr Opin Rheumatol 18(1):54–63PubMedGoogle Scholar
  35. 35.
    Kayali Z, Buckwold VE, Zimmerman B, Schmidt WN (2002) Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology 36(4 Pt 1):978–985PubMedGoogle Scholar
  36. 36.
    Karlsberg PL, Lee WM, Casey DL et al (1995) Cutaneous vasculitis and rheumatoid factor positivity as presenting signs of hepatitis C virus-induced mixed cryoglobulinemia. Arch Dermatol 131(10):1119–1123PubMedCrossRefGoogle Scholar
  37. 37.
    Levey JM, Bjornsson B, Banner B et al (1994) Mixed cryoglobulinemia in chronic hepatitis C infection. A clinicopathologic analysis of 10 cases and review of recent literature. Medicine (Baltimore) 73(1):53–67Google Scholar
  38. 38.
    Cacoub P, Poynard T, Ghillani P et al (1999) Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC group. Multidepartment virus C. Arthritis Rheum 42(10):2204–2212PubMedCrossRefGoogle Scholar
  39. 39.
    Vallat L, Benhamou Y, Gutierrez M et al (2004) Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum 50(11):3668–3678PubMedCrossRefGoogle Scholar
  40. 40.
    Sansonno D, De Vita S, Iacobelli AR et al (1998) Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 160(7):3594–3601PubMedGoogle Scholar
  41. 41.
    Racanelli V, Sansonno D, Piccoli C et al (2001) Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus-infected patients. J Immunol 167(1):21–29PubMedGoogle Scholar
  42. 42.
    Berliner S, Weinberger A, Ben-Bassat M et al (1982) Small skin blood vessel occlusions by cryoglobulin aggregates in ulcerative lesions in IgM-IgG cryoglobulinemia. J Cutan Pathol 9(2):96–103PubMedCrossRefGoogle Scholar
  43. 43.
    Feiner HD (1983) Relationship of tissue deposits of cryoglobulin to clinical features of mixed cryoglobulinemia. Hum Pathol 14(8):710–715PubMedCrossRefGoogle Scholar
  44. 44.
    Szymanski IO, Pullman JM, Underwood JM (1994) Electron microscopic and immunochemical studies in a patient with hepatitis C virus infection and mixed cryoglobulinemia type II. Am J Clin Pathol 102(3):278–283PubMedGoogle Scholar
  45. 45.
    Agnello V, Abel G (1997) Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia. Arthritis Rheum 40(11):2007–2015PubMedCrossRefGoogle Scholar
  46. 46.
    Bernacchi E, Civita LL, Caproni M et al (1999) Hepatitis C virus (HCV) in cryoglobulinaemic leukocytoclastic vasculitis (LCV): could the presence of HCV in skin lesions be related to T CD8+ lymphocytes, HLA-DR and ICAM-1 expression? Exp Dermatol 8(6):480–486PubMedCrossRefGoogle Scholar
  47. 47.
    Sansonno D, Cornacchiulo V, Iacobelli AR et al (1995) Localization of hepatitis C virus antigens in liver and skin tissues of chronic hepatitis C virus-infected patients with mixed cryoglobulinemia. Hepatology 21(2):305–312PubMedGoogle Scholar
  48. 48.
    Wei G, Yano S, Kuroiwa T et al (1997) Hepatitis C virus (HCV)-induced IgG-IgM rheumatoid factor (RF) complex may be the main causal factor for cold-dependent activation of complement in patients with rheumatic disease. Clin Exp Immunol 107(1):83–88PubMedCrossRefGoogle Scholar
  49. 49.
    Levine JW, Gota C, Fessler BJ et al (2005) Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 32(6):1164–1167PubMedGoogle Scholar
  50. 50.
    Landau DA, Saadoun D, Halfon P et al (2008) Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 58(2):604–611PubMedCrossRefGoogle Scholar
  51. 51.
    Chan LS, Vanderlugt CJ, Hashimoto T et al (1998) Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol 110(2):103–109PubMedCrossRefGoogle Scholar
  52. 52.
    Dupin N, Chosidow O, Lunel F et al (1995) Essential mixed cryoglobulinemia. A comparative study of dermatologic manifestations in patients infected or noninfected with hepatitis C virus [see comments]. Arch Dermatol 131(10):1124–1127PubMedCrossRefGoogle Scholar
  53. 53.
    Cattaneo R, Fenini MG, Facchetti F (1986) The cryoglobulinemic vasculitis. Ric Clin Lab 16(2):327–333PubMedGoogle Scholar
  54. 54.
    Buezo GF, Garcia-Buey M, Rios-Buceta L et al (1996) Cryoglobulinemia and cutaneous leukocytoclastic vasculitis with hepatitis C virus infection. Int J Dermatol 35(2):112–115PubMedCrossRefGoogle Scholar
  55. 55.
    Auzerie V, Chiali A, Bussel A et al (2003) Leg ulcers associated with cryoglobulinemia: clinical study of 15 patients and response to treatment. Arch Dermatol 139(3):391–393PubMedCrossRefGoogle Scholar
  56. 56.
    Krunic AL, Medenica MM, Laumann AE, Shaw JC (2003) Cryoglobulinaemic vasculitis, cryofibrinogenaemia and low-grade B-cell lymphoma. Br J Dermatol 148(5):1079–1081PubMedCrossRefGoogle Scholar
  57. 57.
    Baughman RD, Sommer RG (1966) Cryoglobulinemia ­presenting as “factitial ulceration”. Arch Dermatol 94(6): 725–731PubMedCrossRefGoogle Scholar
  58. 58.
    Ellis FA (1964) The cutaneous manifestation of cryoglobulinemia. Arch Dermatol 89:690–697PubMedCrossRefGoogle Scholar
  59. 59.
    Harper JI, Gray W, Wilson-Jones E (1983) Cryoglobulinaemia and angiomatosis. Br J Dermatol 109(4):453–458PubMedCrossRefGoogle Scholar
  60. 60.
    Resnik KS (2009) Intravascular eosinophilic deposits-when common knowledge is insufficient to render a diagnosis. Am J Dermatopathol 31(3):211–217PubMedGoogle Scholar
  61. 61.
    Cohen SJ, Pittelkow MR, Su WP (1991) Cutaneous manifestations of cryoglobulinemia: clinical and histopathologic study of seventy-two patients. J Am Acad Dermatol 25(1 Pt 1):21–27PubMedCrossRefGoogle Scholar
  62. 62.
    Buchsbaum M, Werth V (1994) Erythema nodosum-like nodules associated with vasculitis resulting from mixed cryoglobulinemia. J Am Acad Dermatol 31(3 Pt 1): 493–495PubMedCrossRefGoogle Scholar
  63. 63.
    Boom BW, Brand A, Bavinck JN et al (1988) Severe leukocytoclastic vasculitis of the skin in a patient with essential mixed cryoglobulinemia treated with high-dose gamma-globulin intravenously. Arch Dermatol 124(10):1550–1553PubMedCrossRefGoogle Scholar
  64. 64.
    Mekkes JR, Loots MA, van der Wal AC, Bos JD (2004) Increased incidence of hypercoagulability in patients with leg ulcers caused by leukocytoclastic vasculitis. J Am Acad Dermatol 50(1):104–107PubMedCrossRefGoogle Scholar
  65. 65.
    Claudy A (1999) Coagulation and fibrinolysis in cutaneous vasculitis. Clin Dermatol 17(6):615–618PubMedCrossRefGoogle Scholar
  66. 66.
    Tomizawa K, Sato-Matsumura KC, Kajii N (2003) The coexistence of cutaneous vasculitis and thrombosis in childhood-onset systemic lupus erythematosus with antiphospholipid antibodies. Br J Dermatol 149(2):439–441PubMedCrossRefGoogle Scholar
  67. 67.
    Rocca PV, Siegel LB, Cupps TR (1994) The concomitant expression of vasculitis and coagulopathy: synergy for marked tissue ischemia. J Rheumatol 21(3):556–560PubMedGoogle Scholar
  68. 68.
    Trejo O, Ramos-Casals M, Garcia-Carrasco M et al (2001) Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 80(4):252–262CrossRefGoogle Scholar
  69. 69.
    Bryce AH, Kyle RA, Dispenzieri A, Gertz MA (2006) Natural history and therapy of 66 patients with mixed cryoglobulinemia. Am J Hematol 81(7):511–518PubMedCrossRefGoogle Scholar
  70. 70.
    Iannuzzella F, Vaglio A, Garini G (2010) Management of hepatitis C virus-related mixed cryoglobulinemia. Am J Med 123(5):400–408PubMedCrossRefGoogle Scholar
  71. 71.
    Bessis D, Dereure O, Rivire S et al (2002) Diffuse Bier white spots revealing cryoglobulinaemia. Br J Dermatol 146(5):921–922PubMedCrossRefGoogle Scholar
  72. 72.
    Wager O, Mustakallio KK, Rasanen JA (1968) Mixed IgA-IgG cryoglobulinemia. Immunological studies and case reports of three patients. Am J Med 44(2):179–187PubMedCrossRefGoogle Scholar
  73. 73.
    Bruchfeld A, Lindahl K, Stahle L et al (2003) Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 18(8):1573–1580PubMedCrossRefGoogle Scholar
  74. 74.
    Nir MA, Pick AI, Schreibman S et al (1974) Mixed IgG-IgM cryoglobulinemia with follicular pustular purpura. Arch Dermatol 109(4):539–542PubMedCrossRefGoogle Scholar
  75. 75.
    Crowson AN, Nuovo G, Ferri C, Magro CM (2003) The dermatopathologic manifestations of hepatitis C infection: a clinical, histological, and molecular assessment of 35 cases. Hum Pathol 34(6):573–579PubMedCrossRefGoogle Scholar
  76. 76.
    Abajo P, Porras-Luque JI, Buezo GF et al (1998) Red finger syndrome associated with necrotizing vasculitis in an HIV-infected patient with hepatitis B. Br J Dermatol 139(1):154–155PubMedCrossRefGoogle Scholar
  77. 77.
    Koda H, Kanaide A, Asahi M, Urabe H (1978) Essential IgG cryoglobulinemia with purpura and cold urticaria. Arch Dermatol 114(5):784–786PubMedCrossRefGoogle Scholar
  78. 78.
    Lin RY, Caren CB, Menikoff H (1995) Hypocomplementaemic urticarial vasculitis, interstitial lung disease and hepatitis C. Br J Dermatol 132(5):821–823PubMedCrossRefGoogle Scholar
  79. 79.
    Erkek E, Ayaslioglu E, Erdogan S, Bagci Y (2007) Vasculopathic skin lesions following epilation, leading to a discovery of hepatitis C virus infection. Clin Exp Dermatol 32(2):221–222PubMedCrossRefGoogle Scholar
  80. 80.
    Rieu V, Cohen P, Andre MH et al (2002) Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. Rheumatology (Oxford) 41(3):290–300CrossRefGoogle Scholar
  81. 81.
    Genereau T, Martin A, Lortholary O et al (1998) Temporal arteritis symptoms in a patient with hepatitis C virus associated type II cryoglobulinemia and small vessel vasculitis. J Rheumatol 25(1):183–185PubMedGoogle Scholar
  82. 82.
    Parodi A, Cozzani E, Sorbara S, Rebora A (2005) Hepatitis C virus-related cutaneous vasculitis in the absence of specific antibodies. Clin Exp Dermatol 30(2):188PubMedCrossRefGoogle Scholar
  83. 83.
    Popp JW Jr, Harrist TJ, Dienstag JL et al (1981) Cutaneous vasculitis associated with acute and chronic hepatitis. Arch Intern Med 141(5):623–629PubMedCrossRefGoogle Scholar
  84. 84.
    Daoud MS, El-Azhary RA, Gibson LE et al (1996) Chronic hepatitis C, cryoglobulinemia, and cutaneous necrotizing vasculitis. Clinical, pathologic, and immunopathologic study of twelve patients. J Am Acad Dermatol 34(2 Pt 1): 219–223PubMedCrossRefGoogle Scholar
  85. 85.
    Landau DA, Scerra S, Sene D et al (2010) Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy. J Rheumatol 28:2010Google Scholar
  86. 86.
    Pakula AS, Garden JM, Roth SI (1993) Cryoglobulinemia and cutaneous leukocytoclastic vasculitis associated with hepatitis C virus infection. J Am Acad Dermatol 28(5 Pt 2):850–853PubMedCrossRefGoogle Scholar
  87. 87.
    Sepp NT, Umlauft F, Illersperger B et al (1995) Necrotizing vasculitis associated with hepatitis C virus infection: ­successful treatment of vasculitis with interferon-alpha despite persistence of mixed cryoglobulinemia. Dermatology 191(1):43–45PubMedCrossRefGoogle Scholar
  88. 88.
    von Kobyletzki G, Stucker M, Hoffmann K et al (1998) Severe therapy-resistant necrotizing vasculitis associated with hepatitis C virus infection: successful treatment of the vasculitis with extracorporeal immunoadsorption. Br J Dermatol 138(4):718–719CrossRefGoogle Scholar
  89. 89.
    Chen KR, Carlson JA (2008) Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 9(2):71–92PubMedCrossRefGoogle Scholar
  90. 90.
    Carlson JA, Chen KR (2007) Cutaneous pseudovasculitis. Am J Dermatopathol 29(1):44–55PubMedCrossRefGoogle Scholar
  91. 91.
    Ferri C, Mannini L, Bartoli V et al (1990) Blood viscosity and filtration abnormalities in mixed cryoglobulinemia patients. Clin Exp Rheumatol 8(3):271–281PubMedGoogle Scholar
  92. 92.
    Monteverde A, Rivano MT, Allegra GC et al (1988) Essential mixed cryoglobulinemia, type II: a manifestation of a low-grade malignant lymphoma? Clinical-morphological study of 12 cases with special reference to immunohisto-chemical findings in liver frozen sections. Acta Haematol 79(1):20–25PubMedCrossRefGoogle Scholar
  93. 93.
    Saadoun D, Suarez F, Lefrere F et al (2005) Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 105(1):74–76PubMedCrossRefGoogle Scholar
  94. 94.
    Andre M, Mahammedi H, Aumaitre O et al (2000) A “missed” cryoglobulin: the importance of in vitro calcium concentration. Ann Rheum Dis 59(6):490–492PubMedCrossRefGoogle Scholar
  95. 95.
    Lamprecht P, Gutzeit O, Csernok E et al (2003) Prevalence of ANCA in mixed cryoglobulinemia and chronic hepatitis C virus infection. Clin Exp Rheumatol 21(6 Suppl 32):S89–S94PubMedGoogle Scholar
  96. 96.
    Cacoub P, Renou C, Rosenthal E et al (2000) Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine (Baltimore) 79(1):47–56CrossRefGoogle Scholar
  97. 97.
    Ferri C, Pietrogrande M, Cecchetti R et al (1989) Low-antigen-content diet in the treatment of patients with mixed cryoglobulinemia. Am J Med 87(5):519–524PubMedCrossRefGoogle Scholar
  98. 98.
    Sabry AA, Sobh MA, Sheaashaa HA et al (2002) Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 17(11):1924–1930PubMedCrossRefGoogle Scholar
  99. 99.
    Dammacco F, Tucci FA, Lauletta G et al (2010) Pegylated interferon-alpha, ribavirin, and rituximab combined ­therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 116(3):343–353PubMedCrossRefGoogle Scholar
  100. 100.
    Roccatello D, Baldovino S, Rossi D et al (2004) Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19(12):3054–3061PubMedCrossRefGoogle Scholar
  101. 101.
    Cacoub P, Lidove O, Maisonobe T et al (2002) Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 46(12):3317–3326PubMedCrossRefGoogle Scholar
  102. 102.
    Cacoub P, Saadoun D, Limal N et al (2005) PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 52(3):911–915PubMedCrossRefGoogle Scholar
  103. 103.
    Mazzaro C, Zorat F, Caizzi M et al (2005) Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 42(5):632–638PubMedCrossRefGoogle Scholar
  104. 104.
    Casato M, Lagana B, Pucillo LP, Quinti I (1998) Interferon for hepatitis C virus-negative type II mixed cryoglobulinemia. N Engl J Med 338(19):1386–1387PubMedCrossRefGoogle Scholar
  105. 105.
    Monti G, Saccardo F, Rinaldi G et al (1995) Colchicine in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 13(Suppl 13):S197–S199PubMedGoogle Scholar
  106. 106.
    Attal N, Cruccu G, Haanpaa M et al (2006) EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13(11):1153–1169PubMedCrossRefGoogle Scholar
  107. 107.
    Ferri C, Giuggioli D, Cazzato M et al (2003) HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clin Exp Rheumatol 21(6 Suppl 32):S78–S84PubMedGoogle Scholar
  108. 108.
    Zaja F, De Vita S, Mazzaro C et al (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101(10):3827–3834PubMedCrossRefGoogle Scholar
  109. 109.
    Sansonno D, De Re V, Lauletta G et al (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101(10):3818–3826PubMedCrossRefGoogle Scholar
  110. 110.
    Cacoub P, Delluc A, Saadoun D et al (2008) Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 67(3):283–287PubMedCrossRefGoogle Scholar
  111. 111.
    Bhopale GM, Nanda RK (2005) Emerging drugs for chronic hepatitis C. Hepatol Res 32(3):146–153PubMedCrossRefGoogle Scholar
  112. 112.
    Ferri C, Longombardo G, La Civita L et al (1994) Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease. J Intern Med 236(1):31–36PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  • Konstantinos Linos
    • 1
  • Bernard Cribier
    • 2
  • J. Andrew Carlson
    • 3
  1. 1.Department of PathologyAlbany Medical CollegeAlbanyUSA
  2. 2.Dermatologique CliniqueLes Hopitaux Universtaires de StrasbourgStrasbourgFrance
  3. 3.Division of Dermatology and Dermatopathology, Department of PathologyAlbany Medical CollegeAlbanyUSA

Personalised recommendations